Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Inclusion Criteria: Willing and able to comply with the requirements for this study and written informed consent. Male or female age ≥ 18 years Diagnosis of untreated non severe aplastic anemia. Platelet counts < 50 x 10^9/L at least 2 times consecutively (time interval ≥ 1 week) Exclusion Criteria: Receive immunosuppressive therapy more than 4 weeks before enrollment Treatment with TPO-RA within 1 week before enrollment Inherited bone marrow failure syndromes Bone marrow fibrosis grade ≥ 2 The presence of hemolytic PNH clone The presence of clonal karyotypic abnormalities (del(20q), +8 and -Y are not included in this category) Previously treated with TPO-RA ≥ 4 weeks Previously received immunosuppressive therapy ≥ 12 weeks Ferritin > 1000 ng/ml (The increased level of Ferritin led by infection is not included in this category) Have an allergy to eltrombopag or any other part of this medicine. History of radiotherapy and chemotherapy for malignant solid tumors Cytopenia caused by other non-hematologic diseases, including liver cirrhosis, active rheumatic connective tissue disease, and persistence of infectious diseases, etc Abnormal liver function: ALT or AST > 3 ULN, or TBil > 1.5 ULN after treatment. Abnormal kidney function: Creatinine clearance < 30 ml/min, or serum creatinine (sCr) >1.5 ULN Patients with diabetic nephropathy, neuropathy, or eye disease Patients with poorly controlled hypertension or cardiac arrhythmia Patients with congestive heart failure and the NYHA grade ≥ 3 historically or currently, and LVEF < 45% within 4 weeks before enrollment History of arteriovenous thrombosis within 1 year before enrollment Participation in another clinical trial within 4 months before the start of this trial Pregnant or breast-feeding patients Patients considered to be ineligible for the study by the investigator for reasons other than the above